Sentence examples for bone turnover data not from inspiring English sources

Oral and intravenous bisphosphonates (alendronate, risedronate, pamidronate, ibandronate, and zoledronic acid), given daily or intermittently, were also shown to significantly reduce markers of bone turnover (data not shown) and to increase the BMD compared to baseline and to placebo.

Bone turnover data are summarized in Table 6.

Furthermore, none of the three mutations affected protein stability or turnover (data not shown).

Of note is the observation that the resulting bony metastases do not show preference for particular skeletal sites where high bone turnover occurs, indicating that high bone turnover is not required for the establishment of metastases.

Biochemical markers of bone turnover were not measured.

The mechanism of IL-6 signalling in bone turnover is not yet understood.

This confirms the fact that bone turnover is not excessively reduced with zoledronic acid treatment.

The diminishing effect on BMD due to impaired bone turnover was not shown until six months of polychemotherapy [ 28].

The full picture of bone turnover is not completed as yet, although many factors and interactions are well described.

For bone turnover markers, not the changes in bone markers during treatment, but the pre-treatment values were associated with time-to-progression.

Thus, whereas systemic increased bone resorption resulted in secondary cartilage erosions, local increased bone turnover did not result in cartilage degradation.